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Abstract

Objective We compared the physician-assessed
diagnostic likelihood of SLE resulting from standard
diagnosis laboratory testing (SDLT) to that resulting
from multianalyte assay panel (MAP) with cell-bound
complement activation products (MAP/CB-CAPs), which
reports a two-tiered index test result having 80%
sensitivity and 86% specificity for SLE.
Methods Patients (n=145) with a history of positive
antinuclear antibody status were evaluated clinically
by rheumatologists and randomised to SDLT arm (tests
ordered at the discretion of the rheumatologists) or to
MAP/CB-CAPs testing arm. The primary endpoint was
based on the change in the physician likelihood of SLE on
a five-point Likert scale collected before and after testing.
Changes in pharmacological treatment based on laboratory
results were assessed in both arms. Statistical analysis
consisted of Wilcoxon and Fisher’s exact tests.
Results At enrolment, patients randomised to SDLT
(n=73, age=48±2 years, 94% females) and MAP/CBCAPs testing arms (n=72, 50±2 years, 93% females)
presented with similar pretest likelihood of SLE (1.42±0.06
vs 1.46±0.06 points, respectively; p=0.68). Post-test
likelihood of SLE resulting from randomisation in the MAP/
CB-CAPs testing arm was significantly lower than that
resulting from randomisation to SDLT arm on review of
test results (−0.44±0.10 points vs −0.19±0.07 points)
and at the 12-week follow-up visit (−0.61±0.10 points vs
−0.31±0.10 points) (p<0.05). Among patients randomised
to the MAP/CB-CAPs testing arm, two-tiered positive test
results associated significantly with initiation of prednisone
(p=0.034).
Conclusion Our data suggest that MAP/CB-CAPs
testing has clinical utility in facilitating SLE diagnosis and
treatment decisions.

Introduction
SLE remains one of the most challenging autoimmune rheumatic diseases to diagnose in
rheumatology practice and is a leading cause
of death in young females.1 The difficulties in
the ability of healthcare providers to make a

diagnosis of SLE is primarily related to the low
prevalence of the disease and the heterogeneity of symptoms that are often non-specific
and overlapping with many other conditions
such as fibromyalgia.2 Diagnostic challenges
are also due in part to the lack of diagnostic
criteria and limitations with current diagnostic
immunology testing, primarily antinuclear
(ANA) and anti-double stranded (ds) DNA
antibodies that lack specificity and sensitivity,
respectively.3 It follows that the validation and
introduction in clinical practice of novel SLE
markers or testing methods that facilitate the
diagnosis of the disease is an unmet need for
the rheumatologists. Early diagnosis can identify patients likely to benefit from treatment
(such as hydroxychloroquine (HCQ)) to limit
organ damage and decrease healthcare utilisation.4 In addition, accurate determination
of the unlikely SLE diagnosis in ANA-positive
patients with non-specific symptoms is important and can have direct benefit by decreasing
inappropriate referrals to the rheumatologist.
Complement hyperconsumption due to activation of the complement system is intimately
associated with SLE and measurement of
serum complement levels is now integrated in
modern classification criteria for the disease.5
Over the past two decades, many studies have
reported that quantification of cell-bound
complement activation products (CB-CAPs)
is a valid measure of classical complement
pathway activation and has demonstrated
value in SLE diagnosis and monitoring.3 6 A
multianalyte assay panel (MAP) that combines
CB-CAPs (C4d on erythrocytes (EC4d) and B
cells (BC4d)) with eight autoantibodies has
been developed to assist rheumatologists with
the differential diagnosis of SLE6 and multiple
studies support the clinical validity and
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accuracy of the panel in distinguishing SLE from a variety
of other rheumatic diseases.3 7–10 Furthermore, MAP and
CB-CAPs consistently outperform serum complement
levels for SLE diagnosis. A case–control, retrospective
review of medical charts also suggested the clinical utility
of MAP/CB-CAPs laboratory testing in assisting rheumatologists in real-world practice.11 However, prospective
data comparing standard diagnosis laboratory testing
(SDLT) to MAP/CB-CAPs laboratory testing is lacking. In
this randomised study, our objective was to assess prospectively the clinical utility of diagnostic immunology testing
and MAP/CB-CAPs in assisting rheumatologists with the
diagnosis of SLE. We also evaluated whether treatment
decisions were affected by the treatment arms to which
the patients/physicians were assigned.
Methods
The Clinical Laboratory Assessment and Recommendation for Lupus (CARE for Lupus) was a multicentred, randomised and prospective study in the USA
that enrolled patients referred to board-certified rheumatologists with a suspicion of SLE. Patient consent
was collected for all patients. At enrolment, all patients
presented with a history of ANA positivity within the
prior 6 months and were assessed clinically within
3 months of their referral to rheumatologists. Patients
were randomised to two different groups (1:1) on the
day of enrolment using block randomisation of 20
patients. For the SDLT group, no recommendation was
made to the rheumatologists with regard of which laboratory tests to order and what laboratory to order them
from. The other randomisation group corresponded to
the MAP/CB-CAPs laboratory testing method. Both the
sponsor and investigators were blinded to the randomisation list for the duration of the study. MAP/CB-CAPs
combines CB-CAPs (erythrocyte bound C4d (EC4d) and
B-lymphocyte bound C4d (BC4d)) with eight autoantibodies (ANA, anti-Smith, anti-dsDNA (confirmed using
Crithidia indirect immunofluorescence (IIF)), anticyclic
citrullinated peptide (CCP), anti-centromere B (CENP),
anti-Jo1, anti-Scl-70 and anti-SSB antibodies) to produce
a two-tiered index value, in which a positive test result
(>0 index value combining tier 1 and tier 2) results into
80% sensitivity and 86% specificity in distinguishing SLE
from a control group of patients with other autoimmune
rheumatic diseases.3 Details about the two-tiered method
is provided in the online supplementary figure 1. MAP/
CB-CAPs index value was measured at Exagen (Vista,
California, USA), which runs a clinical laboratory accredited by the College of American Pathologists as currently
approved by the Clinical Laboratory Evaluation Program
in the state of New York.6 For all patients, venous blood
was collected at the time of clinical assessment and
randomisation and was shipped overnight to Exagen in
transportation kits. The MAP/CB-CAPs index value was
reported to clinicians only for the patients randomised to
the MAP/CB-CAPs testing arm. In addition to the index
2

value, autoantibody levels were reported individually and
were considered positive or negative based on the manufacturer cutoffs. EC4d and BC4d were also reported individually as net mean fluorescent intensity (MFI) with
abnormal levels above the 99th percentile of a normal
healthy group (14 net MFI and 60 net MFI, respectively).
ANA titre by indirect immunofluorescence (on NOVA
View, Inova Diagnostics, San Diego, California, USA) was
also reported. The MAP/CB-CAPs index score was measured also from blood of patients randomised to SDLT
arm; however, clinicians remained blinded to test results
for the duration of the study.
Marker results determined in the group of patients
enrolled in the CARE study were compared with a database of 283 754 specimens submitted to the clinical laboratory for diagnosing SLE. All specimens collected for
the study were processed with the daily clinical load and
quality system management in place in the clinical laboratory in accordance to standard operating procedures.
A five-point Likert scale (0: very low; 1: low; 2: moderate;
3: high; 4: very high) estimating the physician likelihood
for SLE was collected pretest and post-test. Per protocol,
all patients presented with a low to moderate likelihood
of SLE at enrolment (1 or 2 points on the Likert scale),
and all cases were adjudicated by lupus experts (AW and
EM) at the time of enrolment. An adjudicator determined whether there was agreement that the patient
met the criteria for low or moderate likelihood of SLE
based on clinical history, physical findings and any laboratory testing prior to enrolment. In all cases when the
first adjudicator disagreed with the investigator and in
a subset of cases when the first adjudicator agreed with
the investigator, a second adjudication was performed
(blinded as to agreement or disagreement). If both adjudicators disagreed with the investigator (too high or too
low likelihood of SLE), then the patient was considered a
screen failure. Both adjudicators remained blinded as to
group assignment and laboratory testing post-enrolment.
During follow-up, the post-test likelihood of SLE was also
collected using the five-point Likert scale and its change
before and after testing (on review of test results and 12
weeks after enrolment) was used to quantify clinical utility.
Patient-reported outcomes measuring health-related
quality of life using five-level EQ-5D (EQ-5D-5L version)
was collected pretesting and post-testing at 12 weeks.
Physician global assessment (PGA) of disease activity (0–3
points scale) was collected at enrolment (pretesting)
and at 12-week follow-up. Initiation of HCQ or prednisone pretesting and post-testing (on review of test results
and 12 weeks after enrolment) was also collected for all
subjects. All physician and patient-reported outcomes
were collected using web-based interface and electronic
data capture (ClinCapture, San Francisco, California,
USA). Statistical analysis (using R) consisted of Wilcoxon,
Kruskal Wallis, Fisher’s exact and linear mixed-effect
models as appropriate.
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Table 1 Demographics at enrolment
SDLT arm

MAP/CB-CAPs
testing arm

Number of patients
Age (years)

73
48.4±1.6

72
50.0±1.8

Gender (% females)

94.5%

93.1%

Caucasians (%)

67.1%

73.6%

African Americans (%)

24.7%

18.1%

Asians (%)

2.7%

2.8%

Others (%)

5.5%

5.6%

Ethnicities

Days since referral*

28±3

33±3

ANA (historical, %)†

100%

100%

PGA (0–3 point)

1.1±0.1

1.2±0.1

EQ5D-5L‡

0.767±0.015

0.764±0.019

Likelihood of SLE (0–5
points)

1.42±0.06

1.46±0.06

Prednisone (%)
Hydroxychloroquine (%)

5.5%
9.6%

5.6%
13.9%

Results are expressed as average (SEM) and percent as
appropriate.
*Per protocol, all patients were referred to the rheumatologist for
less than 3 months.
†Per protocol, all patients had ahistory of ANA positivity.
‡EQ5D-5L was available in 64 and 66 patients randomised to SDLT
and MAP/CB-CAPs arm, respectively.
CB-CAP, cell-bound complement activation products; EQ5D5L, five-level EuroQol five-dimensional questionnaire; MAP,
multianalyte assay panel; PGA, physician global assessment;
SDLT, standard diagnosis laboratory testing.

Results
Patients and laboratory results
A total of 145 subjects were enrolled at 32 sites between
July 2017 and December 2018 and randomised to SDLT
arm and MAP/CB-CAPs testing arm. Enrolment details are
summarised in online supplementary figure 2. At enrolment, pretest likelihood of SLE was similar in the SDLT
and MAP/CB-CAPs testing arms (1.42±0.06 vs 1.46±0.06
points, respectively; p=0.68). Patient demographics are
summarised in table 1. Signs and symptoms at enrolment in each of the randomisation group are presented
in the online supplementary table 1. The components
of the MAP/CB-CAPs panel in each group is presented
in the online supplementary table 2; positivity rate was
comparable across randomisation groups (p>0.50) and
consistent with that of a population of patients tested
in the clinical laboratory during a 6-year period (2012–
2018), except for ANA as determined by IIF (81% vs 60%;
p<0.01). The positivity rate for the two-tiered index value
was 12.5% in the MAP/CB-CAPs testing arm (2.7% tier 1
positive and 9.8% tier 2 positive) and 15.1% in the SDLT
arm (2.8% tier 1 positive and 12.3% tier 2 positive). Diagnostic immunology tests ordered in the group of patients

Table 2 Physician-reported likelihood of SLE pretest and
post-test

SDLT arm
n=73
MAP/CB-CAPs
testing arm
n=72

Pretest;
enrolment

Post-test; review Postof test results
test;12 weeks

1.42±0.06

1.23±0.08
(−0.19±0.07)
1.01±0.10
(−0.44±0.10)

1.46±0.06

1.11±0.10
(−0.31±0.10)
0.85±0.10
(−0.61±0.10)

Results are expressed as mean (SEM) at each study visit and as
change from enrolment (in parenthesis).
CB-CAPs, cell-bound complement activation products; MAP,
multianalyte assay panel; SDLT, standard diagnosis laboratory testing.

randomised to SDLT arm are presented in online supplementary table 3.
Diagnosis
On review of test results, there was a significant decrease
in post-test likelihood of SLE, irrespective of randomisation arm (Wilcoxon paired test; p<0.01). Results are
presented in table 2. Post-test likelihood of SLE resulting
from randomisation to the MAP/CB-CAPs testing arm
was lower than that resulting from randomisation to
the SDLT arm (−0.44±0.10 points vs −0.19±0.07 points,
respectively; p=0.027) and this significant impact on
decreasing the likelihood of SLE remained significant at the 12-week follow-up visit (−0.61±0.10 points vs
−0.31±0.10 points, respectively; p=0.025). At the 12-week
visit, a significant greater decrease in the likelihood of
SLE (decrease ≥1 point from enrolment) was observed
in the group of patients randomised to MAP/CB-CAPs
testing arm (40/72, 56%) when compared with the SDLT
arm (27/73, 37%) (difference=19%; p=0.031). Figure 1
highlights the change in likelihood of SLE post-test by
two-tiered index score. As expected, in the group of
patients randomised to the MAP/CB-CAPs arm, a positive two-tiered test score associated with higher post-test
likelihood of SLE (p=0.008), in contrast to the group of
patients randomised to the SDLT arm (blinded to MAP/
CB-CAPs test results; p=0.271).
Overall, among patients negative for MAP/CB-CAPs
test results (125 subjects), a lower likelihood of SLE
(decrease ≥1 point from enrolment) was detectable at
12 weeks in the group of patients randomised to MAP/
CB-CAPs testing arm (38/63, 60%) when compared with
the SDLT arm (23/62, 37%) (difference=23%) (p=0.012).
None of the patients randomised to the MAP/CB-CAPs
testing arm presented with higher post-test likelihood of
SLE in the presence of negative test results. Conversely,
among patients positive for MAP/CB-CAPs (20 subjects),
a higher likelihood of SLE (increase ≥1 point from
enrolment) was detectable at 12 weeks (4/9, 44%) in
patients randomised to the MAP/CB-CAPs testing arm
when compared with the SDLT arm (1/11, 9%) (difference=35%; p=0.127). Results are presented in the online
supplementary table 4. Linear mixed-effect models also
revealed that the post-test likelihood of SLE decreased in
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Figure 1 Change in SLE likelihood from enrolment to week 12 by two-tiered index test results The change in SLE likelihood
pretest and post-test is indicated. (A) Multianalyte assay panel/cell-bound complement activation products (MAP/CB-CAPs)
randomisation group; (B) standard diagnosis laboratory testing (SDLT) randomisation group. Kruskal-Wallis analysis of variance
p values are provided for each group.

SDLT (estimate: −0.16±0.04 per visit of follow-up; p<0.01)
and MAP/CB-CAPs testing arms (estimate: −0.31±0.04 per
visit of follow-up; p<0.01). Multivariate linear mixed-effect models established that post-test likelihood of SLE
associated with randomisation to MAP/CB-CAPs testing
Table 3 Linear mixed-effect models of SLE likelihood
in relation to testing arm and MAP/CB-CAPs test result
(positive or negative).
Slope estimate
(SEM)

P value

Time from enrolment (per visit followup)

−0.23±0.03

<0.001

Randomisation to MAP/CB-CAPs
testing arm

−0.174±0.080

0.030

Positive MAP/CB-CAPs test results

+0.311±0.116

0.008

CB-CAPs, cell-bound complement activation products; MAP,
multianalyte assay panel.

4

arm and positive MAP/CB-CAPs test result after adjusting
for follow-up period (table 3).
Other outcomes and treatment
At enrolment, patients presenting with a positive MAP/
CB-CAPs test result had higher PGA than those with
negative MAP/CB-CAPs test result (1.44±0.14 (n=20) vs
1.10±0.05 (n=125)) (p=0.030). At the 12-week follow-up,
a greater improvement in PGA was observed in the MAP/
CB-CAPs testing arm (−0.39±0.08 (n=72)) when compared
with the SDLT testing arm (−0.29±0.06 (n=73)) but the
difference was not significant (p=0.39). Prednisone was
started in 10% (7/73) patients randomised to SDLT arm
versus 6% in patients randomised to the MAP/CB-CAPs
(4/72) (p=0.53). HCQ was started in 25% (18/73) patients
randomised to SDLT arm versus 14% (10/72) patients
randomised to MAP/CB-CAPs testing arm (p=0.14). The
impact of the laboratory testing on the initiation of prednisone and HCQ in the group of patients randomised to
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Figure 2 Initiation of prednisone and HCQ by two-tiered test results in MAP/CB-CAPs testing arm. Fisher’s exact p values
comparing the three groups are are provided. Prednisone and HCQ were initiated in 22% and 33% patients testing positive
for MAP/CB-CAPs (positive tier 1 or positive tier 2), respectively. CB-CAPs, cell-bound complement activation products; HCQ,
hydroxychloroquine.

the MAP/CB-CAPs testing arm is presented in figure 2
and revealed that the MAP/CB-CAPs test results associated significantly with initiation of prednisone (p=0.034)
and a similar trend was observed with initiation of HCQ
(p=0.112). The initiation of HCQ or prednisone by
marker in the group of patients randomised in SDLT arm
is presented in online supplementary table 5 and did not
reach significance for any markers (p>0.13).
Finally, in the group of patients randomised to the
MAP/CB-CAPs testing arm, a positive MAP/CB-CAPs
test result associated with increased EQ5D-5L index
score from enrolment to visit 2 (estimate: +0.054±0.024;
p=0.028), and greater improvements were detectable
when compared with the group of patients positive for
the MAP/CB-CAPs test result and randomised to the
SDLT arm (mean+0.099±0.046 (n=8) vs −0.008±0.050
(n=8); p=0.049) (online supplementary table 6).
Discussion
This study is the first prospective multisite randomised
study aimed to compare and quantify the clinical utility
of different laboratory testing methods in facilitating the
diagnosis of SLE. The clinical utility of antibody systems
in the assessment of SLE is undisputed. Although these
biomarkers are known to lack ideal diagnostic accuracy,
rheumatologists have relied on them to facilitate the
differential diagnosis of SLE. Therefore, it is recognised
that new technologies that improve standard diagnostic
laboratory and immunology testing in SLE are needed.
However, the improvement in clinical validity and accuracy of novel diagnostic tests (over standard practice)
on their own is insufficient to satisfy the scrutiny from
stakeholders in the healthcare system, including payors,
clinicians and patients.12 New technologies introduced in
clinical laboratory practice must demonstrate their value
in the real-life setting. We have previously established that
MAP with CB-CAPs has clinical utility in rheumatologist
practices, by retrospective chart review,11 using physician-reported likelihood of SLE for patients evaluated for
signs and symptoms of SLE.

In this study, our objective was to establish the clinical utility of the MAP/CB-CAPs in clinical practice in a
prospective, scientific study. There were some challenges
associated with the design of the study, especially due to
the lack of consensus and heterogeneity regarding the
SDLT in patients who are being considered for a diagnosis of SLE. Therefore, we purposely made no recommendation as to what tests to order or what laboratory
to order them from in the group of patients randomised
to the SDLT arm, to better reflect common clinical practice. Clinical utility was defined probabilistically and
semiquantitatively using the change in the likelihood
of SLE, assessed using five-point Likert scale collected
pretesting and post-testing. All patients enrolled in the
study were referred with an history of ANA positivity and
were considered to have a low to moderate likelihood of
SLE as determined by the enrolling rheumatologists and
the adjudicators, based on prior history and clinical and
demographic features at presentation. Since the criteria
for entry were a positive ANA and a low to moderate
likelihood of SLE, it is not surprising that most of the
patients enrolled in this study were negative for the MAP/
CB-CAPs index score in both arms. This is comparable
to the target population of patients tested in our clinical
laboratory. As expected, the likelihood of SLE decreased
in the group of patients randomised to SDLT arm, and
these data are consistent with the low prevalence of SLE
in the population of ANA-positive patients referred to the
rheumatologist for a suspicion of SLE.
The lower post-test likelihood of SLE in the group of
patients randomised to the MAP/CB-CAPs arm compared
with the SDLT arm was observed early on and was maintained at 12 weeks. Importantly, in the presence of MAP/
CB-CAPs negative test result, we detected a significantly
lower likelihood of SLE in patients randomised to the
MAP/CB-CAPs testing arm when compared with the
SDLT arm, thereby indicating greater confidence that
the diagnosis of SLE is unlikely with the MAP/CB-CAPs
testing. Conversely, greater likelihood of SLE was detectable in the presence of a positive MAP/CB-CAPs test
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result. Altogether, these data are consistent with the
greater diagnostic accuracy of the MAP/CBCAPs panel
and its ability to influence diagnostic decision-making.
We also collected treatment information and our data
revealed that positive two-tiered MAP/CB-CAPs test
results led to initiation of prednisone and HCQ treatment, thus suggesting that the MAP/CB-CAPs test results
in the context of clinical findings and symptoms were
actionable and led to changes in physician’s behaviour
pharmacological intervention in that group of patients.
On clinical grounds, these patients were deemed to have
low to moderate likelihood of SLE. Therefore, it is not
surprising that a positive test result would increase their
estimate of likelihood of SLE and thus initiation of appropriate treatment such as steroids or HCQ. In contrast,
in the group of patients randomised to SDLT, no significant association between the markers and initiation of
prednisone or HCQ was detected. There was also significant improvement in the quality of life in the group of
patients randomised to the MAP/CB-CAPs treatment arm
and given a positive test result, and we speculate that the
laboratory information provided may have decreased the
uncertainty of the diagnosis for the patient.
We acknowledge that there are potential limitations
in our study. First, long-term impact on health status
and patient outcome was not collected after 12 weeks.
Second, the short time frame of the study did not allow us
to collect long-term data, including fulfilment of the classification criteria for SLE or the impact of the diagnostic
strategy on formal health outcome including healthcare
utilisation. However, the improvement in the diagnostic
certainty by rheumatologists with either a negative or positive MAP/CB-CAPs compared with SDLT, and the impact
of the positive test results on the initiation of therapy and
EQ-5D is likely to associate with changes in outcomes. In
conclusion, in this first randomised, prospective, multicentre study, our data suggest the clinical utility of a new
diagnostic intervention to aid community-based rheumatologists and the challenging patients they manage.
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